Zuma-22: A trial testing axicabtagene ciloleucel in people with relapsed or refractory follicular lymphoma

A phase 3 trial comparing axicabtagene ciloleucel against current treatment in adults with relapsed or refractory follicular lymphoma.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05371093

Trial aim and background  

The aim of this trial is to find out how well the drug axicabtagene ciloleucel works in patients with relapsed or refractory follicular lymphoma when compared to the standard treatments. 

Participants will not be able to choose whether they receive the drug, and will be randomised into this group, or the control group where they will receive a current standard treatment

Participants who receive the drug will be followed up for fifteen years.

Who can enter 

Adults with follicular lymphoma which has relapsed after first-line chemoimmunotherapy or after two systemic treatments may be eligible for this trial

Locations 

Recruitment is taking place at the 

  • Birmingham NHS Foundation Trust, Birmingham
  • Cambridge University Hospitals NHS Foundation Trust, Cambridge
    Recruiting
  • University College London Hospitals, London
  • King's College Hospital NHS Foundation Trust, London
  • The Christie NHS Foundation Trust, Manchester
  • The University Hospital Southampton NHS Foundation Trust, Southampton
  • The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust, Oxford

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05371093

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.